Puppo Margherita, Taipaleenmäki Hanna, Hesse Eric, Clézardin Philippe
Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK.
Molecular Skeletal Biology Laboratory, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Br J Pharmacol. 2021 May;178(9):1936-1954. doi: 10.1111/bph.14836. Epub 2019 Dec 11.
Bone metastases are frequent complications in patients with advanced cancer, which can be fatal or may rapidly impede the quality of life of patients. Current treatments for patients with bone metastases are palliative. Therefore, a better understanding of the molecular mechanisms that precede the overt development of skeletal lesions could lead to better therapeutic interventions. In this review, we present evidence that non-coding RNAs (ncRNAs) such as long ncRNAs, microRNAs, and circular RNAs are emerging as master regulators of bone metastasis formation. We highlight potential opportunities for the therapeutic targeting of ncRNAs. Furthermore, we discuss the possibility that ncRNAs may be used as biomarkers in the context of bone metastases, which might provide insight for improving the response to current bone-targeting therapies. LINKED ARTICLES: This article is part of a themed issue on The molecular pharmacology of bone and cancer-related bone diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.9/issuetoc.
骨转移是晚期癌症患者常见的并发症,可能致命或迅速影响患者生活质量。目前针对骨转移患者的治疗是姑息性的。因此,更好地了解骨骼病变明显发展之前的分子机制可能会带来更好的治疗干预措施。在本综述中,我们提供证据表明,长链非编码RNA、微小RNA和环状RNA等非编码RNA(ncRNAs)正成为骨转移形成的主要调节因子。我们强调了针对ncRNAs进行治疗的潜在机会。此外,我们讨论了ncRNAs在骨转移背景下用作生物标志物的可能性,这可能为改善当前骨靶向治疗的反应提供思路。相关文章:本文是关于骨骼与癌症相关骨疾病分子药理学的主题问题的一部分。要查看本节中的其他文章,请访问http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.9/issuetoc。